Shaer Fayez El, Raslan Ismael, Osaimi Nora Al, Bawazeer Ghada, Alayobi Fhakr, Alhogbani Tarek, Kharabsheh Suliman, Habeeb Walid Al
King Fahad Cardiac Center, Department of Cardiac Sciences, College of Medicine, King Saud University Riyadh, Saudi Arabia.
Am J Cardiovasc Dis. 2016 Sep 15;6(3):109-17. eCollection 2016.
Appropriate management of patients with mechanical prosthetic valves on warfarin during dental procedures is crucial. If the patients continue warfarin, they might develop bleeding, while interruption of therapy can cause thromboembolic events. Bridging therapy (mostly heparin) is used in some patients, while others stop medications. There is no unifying protocol. Information on management of patients on warfarin undergoing dental procedures in Saudi Arabia is lacking. Therefore, the current study aimed to provide more insight into various approaches utilized by clinicians to deal with such patients at a large teaching hospital in Riyadh, and to evaluate the frequency and severity of bleeding and thromboembolic complications during different types of dental procedures in this population. This was a cohort study. Patient records were used to collect data on peri-procedural management of patients on warfarin, continuation or interruption of warfarin therapy, as well as bleeding and thromboembolic complications. Fifty medical records were reviewed from March to October 2012. Regarding management, 10% had no proper documentation, 74% underwent bridging therapy, 12% discontinued warfarin therapy, and 4% continued warfarin. Of the patients, 31% had minor bleeding (15% in patients on bridging therapy and 16% in patients continuing warfarin). Thromboembolic complications were documented in 4%, (2% in those on bridging therapy and 2% in those discontinuing warfarin). Patients on bridging therapy (heparin) were admitted to the hospital for a mean of five days, and none of the other patients were admitted. Adopting the protocol to continue warfarin caused bleeding tendency that was controlled with the usual measures, with more cost effectiveness, and no thromboembolic risks.
对于服用华法林的机械人工瓣膜患者,在牙科手术期间进行适当管理至关重要。如果患者继续服用华法林,可能会发生出血,而中断治疗则可能导致血栓栓塞事件。一些患者采用桥接治疗(主要是肝素),而其他患者则停止用药。目前尚无统一的方案。沙特阿拉伯缺乏关于服用华法林的患者接受牙科手术管理的信息。因此,本研究旨在更深入了解利雅得一家大型教学医院的临床医生处理此类患者所采用的各种方法,并评估该人群在不同类型牙科手术期间出血和血栓栓塞并发症的发生频率及严重程度。这是一项队列研究。通过患者记录收集服用华法林患者围手术期管理、华法林治疗的继续或中断以及出血和血栓栓塞并发症的数据。回顾了2012年3月至10月的50份病历。在管理方面,10%没有适当的记录,74%接受了桥接治疗,12%停止了华法林治疗,4%继续服用华法林。在这些患者中,31%有轻微出血(接受桥接治疗的患者中15%,继续服用华法林的患者中16%)。有4%记录了血栓栓塞并发症(接受桥接治疗的患者中2%,停止服用华法林的患者中2%)。接受桥接治疗(肝素)的患者平均住院5天,其他患者均未住院。采用继续服用华法林的方案会导致出血倾向,但通过常规措施可得到控制,且更具成本效益,并无血栓栓塞风险。